Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors / Science Translational Medecine
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch
Monday, March 9, 2026, 4:22 am / permalink 20364 / 6 stories in 2 days
Elizabeth McKenna: New Cancer Grand Challenges Teams Announced / OncoDaily
oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]
#healthcare #biotech #drugdevelopment #oncology #healthcarefinance #cancerresearch #researchfunding
Saturday, March 7, 2026, 11:22 am / permalink 20326 / 67 stories in 3 days
ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS / OncoDaily
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Saturday, March 7, 2026, 9:22 am / permalink 20321 / 3 stories in 3 days
New FDA bonus pilot to address 'workforce challenges' / Endpoints
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
#healthcare #pharmaceuticals #governmentpolicy #biotech #drugdevelopment #fda #healthcarefinance
Saturday, March 7, 2026, 12:23 am / permalink 20312 / 2 stories in 4 days
New AI tool predicts best pancreatic cancer treatment / Medical Express
medicalxpress - A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.
#healthcare #biotech #digitalhealth #medicaldevices #oncology #pancreaticcancer
Saturday, March 7, 2026, 12:23 am / permalink 20310 / 3 stories in 4 days
FDA lifts hold on Intellia trial / Beckers
Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Saturday, March 7, 2026, 12:23 am / permalink 20309 / 2 stories in 4 days
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology / MedCity
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #healthcarefinance #infectiousdisease
Saturday, March 7, 2026, 12:22 am / permalink 20307 / 3 stories in 4 days
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma / MedCity
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #healthcarefinance
Saturday, March 7, 2026, 12:22 am / permalink 20306 / 4 stories in 4 days
FDA vaccine chief to step down in April / Beckers
Ella Jeffries / beckershospitalreview - Vinay Prasad, MD, the FDA’s top regulator of vaccines and cell and gene therapies, will step down at the end of April, an agency spokesperson confirmed to Becker’s. Dr. Prasad joined the agency in 2025 on a one-year sabbatical from the University of Calif…
#healthcare #publichealth #governmentpolicy #biotech #drugdevelopment #fda #vaccinesafety #infectiousdisease
Friday, March 6, 2026, 6:23 pm / permalink 20292 / 3 stories in 4 days
AI blood test finds silent liver disease years before symptoms / Science Daily Cancer
sciencedaily - Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go unnoticed until serious damage occurs. By analyzing genome-wid…
#healthcare #publichealth #biotech #digitalhealth #medicaldevices #healthcarefinance
Friday, March 6, 2026, 1:22 am / permalink 20251 / 5 stories in 5 days
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy / LiveScience
livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #infanthealth
Thursday, March 5, 2026, 4:23 pm / permalink 20233 / 4 stories in 5 days
Novo Nordisk inks $2.1B oral obesity drug deal / Beckers
Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance
Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 21 stories in 8 days
Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours / ESMO
esmo - Findings from the PYNNACLE study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, March 2, 2026, 2:22 am / permalink 19973 / 8 stories in 9 days
Novartis closes Avidity deal as rare heart disease spinout launches / Endpoints
Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #healthcarefinance
Monday, March 2, 2026, 12:23 am / permalink 19968 / 2 stories in 9 days
Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily
oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 11 days
First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results / Medical Express
medicalxpress - A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This is the first time live ste…
#healthcare #biotech #drugdevelopment #infanthealth
Saturday, February 28, 2026, 1:22 am / permalink 19931 / 2 stories in 11 days
Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 11 days
Novartis to build $23B radioligand therapy site / Beckers
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 12:23 am / permalink 19926 / 3 stories in 11 days
Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints
Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 11 days
Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus / OncoDaily
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #digitalhealth #healthcarefinance
Friday, February 27, 2026, 11:22 pm / permalink 19912 / 6 stories in 11 days